IMR
vs
S
S&P/ASX 300
IMR
Over the past 12 months, IMR has significantly outperformed S&P/ASX 300, delivering a return of +31% compared to S&P/ASX 300's +1% growth.
Stocks Performance
IMR vs S&P/ASX 300
Performance Gap
IMR vs S&P/ASX 300
Performance By Year
IMR vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Imricor Medical Systems Inc
Glance View
Imricor Medical Systems makes tools for doctors who treat heart rhythm disorders inside an MRI scanner. Its main product is a system built around specialized catheters, monitoring equipment, and software that let electrophysiologists map and ablate heart tissue while seeing the heart with MRI instead of x-ray. The company focuses on procedures where doctors need precise real-time imaging of the heart during treatment. Its customers are hospitals and cardiac centers that perform complex electrophysiology procedures, along with physicians who specialize in arrhythmia care. Imricor sells its devices and related accessories, and it can also earn recurring revenue from disposable parts, service, training, and ongoing support tied to the procedure workflow. Because its products are used in a highly specialized clinical setting, sales depend on adoption by hospital teams and the availability of MRI-based treatment programs. What makes Imricor different is that it sits at the intersection of medical devices, imaging, and heart ablation. Instead of competing as a general heart-device maker, it is trying to make MRI-guided cardiac procedures practical, which could let doctors see soft tissue more clearly than with traditional x-ray guidance. That gives the company a focused role in a niche part of the cardiac treatment market.
